{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:03:20Z","timestamp":1775217800720,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012910","name":"National Defense Medical College","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012910","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Standard treatment for metastatic biliary tract cancer is systemic chemotherapy, not local therapy, such as surgery or radiation therapy. This is because long-term survival is not expected with local therapy. We present the case of a 49-year-old man who underwent extended right hepatectomy with extrahepatic bile duct resection for hilar cholangiocarcinoma. Postoperative adjuvant chemotherapy with oral S-1 for six months was completed. At 20\u00a0months post-operation, para-aortic lymphadenopathy was detected, and endoscopic ultrasound-guided biopsy confirmed lymph node recurrence. Gemcitabine and cisplatin were administered for six months, resulting in partial tumor regression. As no other lesions were identified, radiotherapy with a total dose of 55\u00a0Gy in 22 fractions was performed. At 37\u00a0months following the completion of radiotherapy, the patient remained disease-free based on imaging. This case suggests that the addition of local radiotherapy to systemic chemotherapy may be beneficial for patients with oligometastatic recurrence of hilar cholangiocarcinoma.<\/jats:p>","DOI":"10.1007\/s12328-026-02280-w","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:36:09Z","timestamp":1769837769000},"page":"395-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term survival following chemoradiotherapy for postoperative recurrence of hilar cholangiocarcinoma"],"prefix":"10.1007","volume":"19","author":[{"given":"Kazuki","family":"Asakura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4434-0803","authenticated-orcid":false,"given":"Takahiro","family":"Einama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanae","family":"Shinada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Yonamine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takazumi","family":"Tsunenari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikiya","family":"Takao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saburo","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoji","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"2280_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:127\u201340.","journal-title":"Ann Oncol"},{"key":"2280_CR2","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1245\/s10434-020-08207-0","volume":"27","author":"K Morino","year":"2020","unstructured":"Morino K, Seo S, Yoh T, et al. Proposed definition for oligometastatic recurrence in biliary tract cancer based on results of locoregional treatment: a propensity-score-stratified analysis. Ann Surg Oncol. 2020;27:1908\u201317.","journal-title":"Ann Surg Oncol"},{"key":"2280_CR3","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2021.2234","volume":"14","author":"Y Sota","year":"2021","unstructured":"Sota Y, Einama T, Kobayashibayashi K, et al. Recurrent cholangiocarcinoma with long-term survival by multimodal treatment: a case report. Mol Clin Oncol. 2021;14:72.","journal-title":"Mol Clin Oncol"},{"key":"2280_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023;401:195\u2013203.","journal-title":"Lancet"},{"key":"2280_CR5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jamcollsurg.2015.09.005","volume":"221","author":"B Groot Koerkamp","year":"2015","unstructured":"Groot Koerkamp B, Wiggers JK, Allen PJ, et al. Recurrence rate and pattern of Perihilar cholangiocarcinoma after curative intent resection. J Am Coll Surg. 2015;221:1041\u20139.","journal-title":"J Am Coll Surg"},{"key":"2280_CR6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.surg.2017.08.011","volume":"163","author":"K Komaya","year":"2018","unstructured":"Komaya K, Ebata T, Yokoyama Y, et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery. 2018;163:732\u20138.","journal-title":"Surgery"},{"key":"2280_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"2280_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2023;30:102\u201310.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2280_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:694\u2013704.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2280_CR10","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365.","journal-title":"Lancet"},{"key":"2280_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2022.101844","volume":"44","author":"DB Hewitt","year":"2022","unstructured":"Hewitt DB, Aziz H, Brown ZJ, et al. Role of genetic testing in hepatic, pancreatic, and biliary cancers. Surg Oncol. 2022;44:101844.","journal-title":"Surg Oncol"},{"key":"2280_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-015-0507-8","volume":"13","author":"T Noji","year":"2015","unstructured":"Noji T, Tsuchikawa T, Mizota T, et al. Surgery for recurrent biliary carcinoma: results for 27 recurrent cases. World J Surg Oncol. 2015;13:82.","journal-title":"World J Surg Oncol"},{"key":"2280_CR13","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00432-020-03285-9","volume":"146","author":"C Franzese","year":"2020","unstructured":"Franzese C, Bonu ML, Comito T, et al. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. J Cancer Res Clin Oncol. 2020;146:2289\u201397.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2280_CR14","first-page":"1987","volume":"46","author":"Y Hashimoto","year":"2019","unstructured":"Hashimoto Y, Kishimoto T, Murotani M, et al. A case of long-term survival of liver metastasis from biliary carcinoma after pancreaticoduodenectomy treated by multimodal therapy. Gan Kagaku Ryoho. 2019;46:1987\u20139.","journal-title":"Gan Kagaku Ryoho"},{"key":"2280_CR15","first-page":"340","volume":"47","author":"H Ishida","year":"2020","unstructured":"Ishida H, Seyama Y, Ome Y, et al. A case of pulmonary metastasis from hilar cholangiocarcinoma treated by stereotactic body radiotherapy. Gan Kagaku Ryoho. 2020;47:340\u20132.","journal-title":"Gan Kagaku Ryoho."},{"key":"2280_CR16","first-page":"1795","volume":"50","author":"K Sakai","year":"2023","unstructured":"Sakai K, Gotoh K, Toshiyama R, et al. A case of long-term survival with multidisciplinary treatment for postoperative local recurrence of intrahepatic cholangiocarcinoma. Gan Kagaku Ryoho. 2023;50:1795\u20137.","journal-title":"Gan Kagaku Ryoho."},{"key":"2280_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","volume":"19","author":"K Yoshida","year":"2016","unstructured":"Yoshida K, Yamaguchi K, Okumura N, et al. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19:329\u201338.","journal-title":"Gastric Cancer"},{"key":"2280_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/1096-9098(200010)75:2<89::AID-JSO3>3.0.CO;2-V","volume":"75","author":"H Shinchi","year":"2000","unstructured":"Shinchi H, Takao S, Nishida H, et al. Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma. J Surg Oncol. 2000;75:89\u201394.","journal-title":"J Surg Oncol"},{"key":"2280_CR19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.radonc.2014.01.003","volume":"110","author":"Y Yoshioka","year":"2014","unstructured":"Yoshioka Y, Ogawa K, Oikawa H, et al. Factors influencing survival outcome for radiotherapy for biliary tract cancer: a multicenter retrospective study. Radiother Oncol. 2014;110:546\u201352.","journal-title":"Radiother Oncol"},{"key":"2280_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.ejso.2016.12.008","volume":"43","author":"S Kobayashi","year":"2017","unstructured":"Kobayashi S, Tomokuni A, Gotoh K, et al. A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer. Eur J Surg Oncol. 2017;43:763\u201371.","journal-title":"Eur J Surg Oncol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02280-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02280-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02280-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:25:03Z","timestamp":1775215503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02280-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2280"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02280-w","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by the Institutional Review Board of the National Defense Medical College (approval no. 4610), and conducted following the human and ethical principles of the Declaration of Helsinki. We obtained written informed consent from all patients, including the present case, to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from four patients for the publication of detailed clinical information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}